Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes

COMMENTED

Type 2 Diabetes

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Lancet Diabetes Endocrinol.

Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Køber L, Petrie MC, McMurray JJV

doi: 10.1016/S2213-8587(19)30249-9.

Type 2 Diabetes

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

Lancet Diabetes Endocrinol

Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, Lam CSP, Lopes RD, McMurray JJV, Pratley RE, Rosenstock J, Gerstein HC

doi: 10.1016/S2213-8587(21)00203-5

Type 1 Diabetes

Risk factors for decline in renal function among young adults with type 1 diabetes

J Diabetes Complications.

Schwandt A, Bergis D, Denkinger M, Gollisch KSC, Sandig D, Stingl H, Zimny S, Holl RW

doi: 10.1016/j.jdiacomp.

COMMENTED

Type 2 Diabetes

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Circulation.

Mann JFE, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR

doi: 10.1161/CIRCULATIONAHA.

Type 2 Diabetes

Metformin Use and Cardiovascular Events in Patients with Type 2 Diabetes and Chronic Kidney Disease

Diabetes Obes Metab.

Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, Eckardt KU, McMurray JJV, Weinrauch LA, Liu J, Claggett B, Lewis EF, Pfeffer MA

doi: 10.1111/dom.13642.

Type 2 Diabetes

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial

J Am Soc Nephrol.

Wanner C, Heerspink HJL, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, Hantel S, Woerle HJ, Broedl UC, von Eynatten M, Groop PH; EMPA-REG OUTCOME Investigators

doi: 10.1681/ASN.2018010103.

COMMENTED

Diabetes - GeneralType 2 Diabetes

Use of Vascular Assessments and Novel Biomarkers to Predict Cardiovascular Events in Type 2 Diabetes: The SUMMIT VIP Study

Diabetes Care.

Shore AC, Colhoun HM, Natali A, Palombo C, Khan F, Östling G, Aizawa K, Kennbäck C, Casanova F, Persson M, Gooding K, Gates PE, Looker H, Dove F, Belch J, Pinnola S, Venturi E, Kozakova M, Goncalves I, Kravic J, Björkbacka H, Nilsson J; SUMMIT Consortium

doi: 10.2337/dc18-0185.

Type 1 Diabetes

Serum Uromodulin Predicts Less Coronary Artery Calcification and Diabetic Kidney Disease Over 12 years in Adults With Type 1 Diabetes: The CACTI Study

Diabetes Care.

Bjornstad P, Wiromrat P, Johnson RJ, Sippl R, Cherney DZ, Wong R, Rewers MJ, Snell-Bergeon JK

doi: 10.2337/dc18-1527.

COMMENTED

Diabetes - GeneralType 2 Diabetes

Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes

N Engl J Med.

Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson AM, Zethelius B, Miftaraj M, McGuire DK, Rosengren A, Gudbjörnsdottir S

doi: 10.1056/NEJMoa1800256.

Related content

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

Risk factors for decline in renal function among young adults with type 1 diabetes

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Metformin Use and Cardiovascular Events in Patients with Type 2 Diabetes and Chronic Kidney Disease

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial

Use of Vascular Assessments and Novel Biomarkers to Predict Cardiovascular Events in Type 2 Diabetes: The SUMMIT VIP Study

Serum Uromodulin Predicts Less Coronary Artery Calcification and Diabetic Kidney Disease Over 12 years in Adults With Type 1 Diabetes: The CACTI Study

Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes